RXRX vs. INTU

In the year-to-date period, RXRX achieves a -15.24% return, which is significantly lower than INTU's -0.36% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Intuit Inc. (INTU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RXRX Sharpe Ratio is -0.28, which is lower than the INTU Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of RXRX and INTU, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

RXRX has not paid dividends to shareholders, while INTU's dividend yield for the trailing twelve months is around 0.64%.

The maximum RXRX drawdown since its inception was -90.39%, which is greater than INTU's maximum drawdown of -75.29%. Use the drawdown chart below to compare losses from any high point for RXRX and INTU. For additional features, visit the drawdowns tool.

Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 37.94% compared to Intuit Inc. (INTU) at 14.67%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than INTU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and Intuit Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.